KCM
ALDX icon

Kennondale Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Kennondale Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-56,729
Closed -$217K – 83
2025
Q2 		$217K Sell
56,729
-94,551
-63% -$244K 0.22% 81
2025
Q1 		$870K Hold
151,280
– – 0.95% 37
2024
Q4 		$755K Buy
+151,280
New +$776K 0.82% 52

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Kennondale Capital Management's ALDX Position: Q3 2025 in Review

Kennondale Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q3 2025, closing a stake of 56,729 shares — an estimated $217K sold.

Kennondale Capital Management first reported a position in ALDX in Q4 2024 and held it in 3 quarters. The position peaked at $870K in Q1 2025. 130 funds tracked by Wall St. Rank hold ALDX as of Q3 2025.

  • Kennondale Capital Management reported no remaining Aldeyra Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Kennondale Capital Management sold 56,729 Aldeyra Therapeutics shares in Q3 2025, an estimated $217K.
  • Kennondale Capital Management first reported a position in Aldeyra Therapeutics in Q4 2024 and held it in 3 quarters.
  • Kennondale Capital Management's Aldeyra Therapeutics position peaked at $870K in Q1 2025.
  • 130 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2025.

Based on Kennondale Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.